Shares of Cullinan Oncology Inc. (NASDAQ:CGEM) rose 11.3% to close at $33.11 on June 4 as an update on its EGFR inhibitor, CLN-081, suggested it may prove competitive with Johnson & Johnson's recently approved treatment, Rybrevant (amivantamab), for adults with non-small-cell lung cancer (NSCLC) whose tumors bear EGFR exon 20 insertion mutations.
Bad regulatory news didn’t quash hopes for Travere Therapeutics Inc. with sparsentan, its dual-acting antagonist of the endothelin type A and angiotensin II type 1 receptors for focal segmental glomerulosclerosis (FSGS), a disease of kidney scarring.
The bad cohort 1 news from Spectrum Pharmaceuticals Inc. in late April with poziotinib in the phase II Zenith20 study turned itself around in a stock-boosting way as the Henderson, Nev.-based firm unveiled data from cohort 2.
It is equally fair to say that lung cancer treatment has come a long way, and that it has a long way to go. Speaking at a joint conference by the International Association for the Study of Lung Cancer and the American Association for Cancer Research on lung cancer translational research, William Pao remembered the stark realities of being an oncology fellow at Memorial Sloan-Kettering Cancer Center just 20 years ago, when the main lung cancer “procedure” done by trainees was to get a DNR, or do-not-resuscitate order, from their patients.
